

Carol Aghajanian

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7588687/publications.pdf>

Version: 2024-02-01

73
papers

7,271
citations

147801

31
h-index

88630

70
g-index

74
all docs

74
docs citations

74
times ranked

8524
citing authors

#	ARTICLE	IF	CITATIONS
1	Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 2495-2505.	27.0	1,854
2	Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet</i> , The, 2017, 390, 1949-1961.	13.7	1,261
3	Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 2403-2415.	27.0	627
4	Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient. <i>Cell</i> , 2017, 170, 927-938.e20.	28.9	368
5	Phase II Trial of Bevacizumab in Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 2259-2265.	1.6	297
6	A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation â€” An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2015, 137, 386-391.	1.4	224
7	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. <i>Cell</i> , 2022, 185, 563-575.e11.	28.9	223
8	Diverse <i>BRCA1</i> and <i>BRCA2</i> Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 6708-6720.	7.0	194
9	Olaparib and Î±-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. <i>Lancet Oncology</i> , The, 2019, 20, 570-580.	10.7	191
10	BRAF Mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer. <i>Cancer</i> , 2013, 119, 548-554.	4.1	169
11	Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 5939-5947.	7.0	100
12	Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center. <i>Gynecologic Oncology</i> , 2016, 140, 436-442.	1.4	97
13	A novel representation of inter-site tumour heterogeneity from pre-treatment computed tomography textures classifies ovarian cancers by clinical outcome. <i>European Radiology</i> , 2017, 27, 3991-4001.	4.5	92
14	Therapeutic Implications of Germline Testing in Patients With Advanced Cancers. <i>Journal of Clinical Oncology</i> , 2021, 39, 2698-2709.	1.6	83
15	Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 710-722.	10.7	70
16	Sequential Ipilimumab After Chemoradiotherapy in Curative-Intent Treatment of Patients With Node-Positive Cervical Cancer. <i>JAMA Oncology</i> , 2020, 6, 92.	7.1	69
17	Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 2279-2286.	1.6	63
18	Molecular profiling and molecular classification of endometrioid ovarian carcinomas. <i>Gynecologic Oncology</i> , 2019, 154, 516-523.	1.4	62

#	ARTICLE	IF	CITATIONS
19	Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer. <i>JAMA Oncology</i> , 2018, 4, 196.	7.1	60
20	Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer. , 2020, 8, e001126.		54
21	A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2009, 115, 215-220.	1.4	50
22	Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2017, 146, 477-483.	1.4	50
23	Clinicopathologic and Genomic Analysis of TP53-Mutated Endometrial Carcinomas. <i>Clinical Cancer Research</i> , 2021, 27, 2613-2623.	7.0	49
24	The role of systemic chemotherapy in the management of granulosa cell tumors. <i>Gynecologic Oncology</i> , 2015, 136, 505-511.	1.4	45
25	Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib. <i>JAMA Oncology</i> , 2021, 7, 1772.	7.1	44
26	Massively parallel sequencing analysis of mucinous ovarian carcinomas: genomic profiling and differential diagnoses. <i>Gynecologic Oncology</i> , 2018, 150, 127-135.	1.4	41
27	Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study 0229N. <i>Gynecologic Oncology</i> , 2015, 138, 24-29.	1.4	40
28	Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway. <i>Cancer</i> , 2020, 126, 1274-1282.	4.1	37
29	Machine learning-based prediction of microsatellite instability and high tumor mutation burden from contrast-enhanced computed tomography in endometrial cancers. <i>Scientific Reports</i> , 2020, 10, 17769.	3.3	35
30	Phase II study of axlimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology/gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2020, 158, 562-569.	1.4	35
31	Development of a risk stratification system to guide treatment for female germ cell tumors. <i>Gynecologic Oncology</i> , 2015, 138, 566-572.	1.4	34
32	A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors. <i>Investigational New Drugs</i> , 2018, 36, 1016-1025.	2.6	34
33	Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial. , 2020, 8, e000829.		34
34	Risk-Reducing Bilateral Salpingo-Oophorectomy for Ovarian Cancer: A Review and Clinical Guide for Hereditary Predisposition Genes. <i>JCO Oncology Practice</i> , 2022, 18, 201-209.	2.9	34
35	Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models. <i>Scientific Reports</i> , 2019, 9, 18882.	3.3	33
36	Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade. <i>Gynecologic Oncology</i> , 2019, 152, 251-258.	1.4	33

#	ARTICLE	IF	CITATIONS
37	Genomic landscape of endometrial carcinomas of no specific molecular profile. <i>Modern Pathology</i> , 2022, 35, 1269-1278.	5.5	33
38	Iniparib plus paclitaxel and carboplatin as initial treatment of advanced or recurrent uterine carcinosarcoma: A Gynecologic Oncology Group Study. <i>Gynecologic Oncology</i> , 2012, 126, 424-427.	1.4	32
39	Incidence of pelvic lymph node metastasis using modern FIGO staging and sentinel lymph node mapping with ultrastaging in surgically staged patients with endometrioid and serous endometrial carcinoma. <i>Gynecologic Oncology</i> , 2020, 157, 619-623.	1.4	32
40	BRCA Mutations, Homologous DNA Repair Deficiency, Tumor Mutational Burden, and Response to Immune Checkpoint Inhibition in Recurrent Ovarian Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 665-679.	3.0	29
41	Mutant FOXL2C134W Hijacks SMAD4 and SMAD2/3 to Drive Adult Granulosa Cell Tumors. <i>Cancer Research</i> , 2020, 80, 3466-3479.	0.9	29
42	Independent radiologic review: Bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2014, 133, 105-110.	1.4	23
43	Retreatment with carboplatin and paclitaxel for recurrent endometrial cancer: A retrospective study of the Memorial Sloan Kettering Cancer Center experience. <i>Gynecologic Oncology Reports</i> , 2019, 28, 120-123.	0.6	23
44	A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2019, 152, 548-553.	1.4	23
45	Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery. <i>Journal of Gynecologic Oncology</i> , 2020, 31, e17.	2.2	22
46	A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D. <i>Gynecologic Oncology</i> , 2017, 144, 96-100.	1.4	21
47	Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 163, 490-497.	1.4	20
48	Genetic and molecular subtype heterogeneity in newly diagnosed early- and advanced-stage endometrial cancer. <i>Gynecologic Oncology</i> , 2021, 161, 535-544.	1.4	16
49	TSC2-mutant uterine sarcomas with JAZF1-SUZ12 fusions demonstrate hybrid features of endometrial stromal sarcoma and PEComa and are responsive to mTOR inhibition. <i>Modern Pathology</i> , 2022, 35, 117-127.	5.5	16
50	A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2017, 146, 554-559.	1.4	15
51	Subsequent therapies and survival after immunotherapy in recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2019, 155, 51-57.	1.4	14
52	The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma. <i>Gynecologic Oncology</i> , 2020, 159, 101-111.	1.4	14
53	Tumor Inhibition by Enzalutamide in a Xenograft Model of Ovarian Cancer. <i>Cancer Investigation</i> , 2016, 34, 517-520.	1.3	12
54	Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT17767676). <i>Overlook</i> 10 Tf 50	0.6	11

#	ARTICLE	IF	CITATIONS
55	A Phase I Evaluation of Extended Field Radiation Therapy With Concomitant Cisplatin Chemotherapy Followed by Paclitaxel and Carboplatin Chemotherapy in Women With Cervical Carcinoma Metastatic to the Para-aortic Lymph Nodes: An NRG Oncology/Gynecologic Oncology Group Study. <i>Gynecologic Oncology</i> , 2018, 151, 202-207.	1.4	10
56	Phase II evaluation of dalantercept in the treatment of persistent or recurrent epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2018, 150, 466-470.	1.4	10
57	A phase I open-label study of selinexor with paclitaxel and carboplatin in patients with advanced ovarian or endometrial cancers. <i>Gynecologic Oncology</i> , 2021, 160, 71-76.	1.4	9
58	Pre-clinical activity of the oral DNA-PK inhibitor, peposertib (M3814), combined with radiation in xenograft models of cervical cancer. <i>Scientific Reports</i> , 2022, 12, 974.	3.3	8
59	A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2017, 144, 101-106.	1.4	7
60	Understanding Inherited Risk in Unselected Newly Diagnosed Patients With Endometrial Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-15.	3.0	7
61	Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 949-958.	2.5	7
62	Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2. <i>Gynecologic Oncology</i> , 2021, 161, 668-675.	1.4	7
63	Diagnosis and management of an endometrial cancer patient with Cowden syndrome. <i>Gynecologic Oncology</i> , 2021, 163, 14-21.	1.4	6
64	Association of hCG Surveillance with Emotional, Reproductive, and Sexual Health in Women Treated for Gestational Trophoblastic Neoplasia. <i>Journal of Women's Health</i> , 2018, 27, 387-393.	3.3	5
65	Utility of serum CA-125 monitoring in patients with ovarian cancer undergoing immune checkpoint inhibitor therapy. <i>Gynecologic Oncology</i> , 2020, 158, 303-308.	1.4	4
66	Pattern of disease and response to pembrolizumab in recurrent cervical cancer. <i>Gynecologic Oncology Reports</i> , 2021, 37, 100831.	0.6	4
67	Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety. <i>Cancer Medicine</i> , 2021, 10, 7162-7173.	2.8	4
68	Validation of a Population-Based Data Source to Examine National Cancer Clinical Trial Participation. <i>JAMA Network Open</i> , 2022, 5, e223687.	5.9	4
69	Endometrial Stromal Sarcoma. <i>American Journal of Cancer</i> , 2004, 3, 13-23.	0.4	2
70	A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 157, 214-221.	1.4	2
71	Exploring the clinical significance of serous tubal intraepithelial carcinoma associated with advanced high-grade serous ovarian cancer: A Memorial Sloan Kettering Team Ovary Study. <i>Gynecologic Oncology</i> , 2021, 160, 696-703.	1.4	2
72	Outcomes of incidentally detected ovarian cancers diagnosed at time of risk-reducing salpingo-oophorectomy in BRCA mutation carriers. <i>Gynecologic Oncology</i> , 2021, 161, 521-526.	1.4	2

#	ARTICLE	IF	CITATIONS
73	Efficacy and safety of rucaparib maintenance treatment in patients from ARIEL3 with platinum-sensitive, recurrent ovarian carcinoma not associated with homologous recombination deficiency.. Journal of Clinical Oncology, 2022, 40, 5544-5544.	1.6	0